Moolec Science (MLEC) EBITDA Margin (2023 - 2024)
Moolec Science's (MLEC) quarterly EBITDA Margin came in at 86.04% in Q4 2024, down 97157.0% year-on-year from N/an in Q1 2024, and up 195.14% quarter-over-quarter from 90.44% in Q3 2024.
Moolec Science (MLEC) EBITDA Margin (2023 - 2024) Analysis & Trends
Moolec Science has disclosed EBITDA Margin across 2 years of filings, most recently posting 86.04% for Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 86.04% |
| Sep 30, 2024 | -90.44% |
| Mar 31, 2024 | 40.17% |
| Dec 31, 2023 | 1,057.61% |
| Sep 30, 2023 | -93.20% |